Clinical Report: FDA Approval of Pembrolizumab-Belzutifan for ccRCC

Overview

The FDA has approved the combination of pembrolizumab and belzutifan as an adjuvant treatment for adult patients with clear cell renal cell carcinoma at high risk of recurrence after surgery. This approval is based on the phase 3 LITESPARK-022 trial.

Background

Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer, with clear cell renal cell carcinoma (ccRCC) being the most common subtype. Approximately 30% of patients with ccRCC experience disease recurrence within five years following nephrectomy.

Data Highlights

Key Findings

• The FDA approved pembrolizumab plus belzutifan for high-risk ccRCC patients post-surgery.
• The LITESPARK-022 trial included 1,841 participants with ccRCC.
• The combination therapy resulted in a 28% decrease in the risk of recurrence, metastasis, or death.
• 81% of patients on the combination therapy were cancer-free at 24 months compared to 74% on placebo.
• This is the first approval for a PD-1 and HIF-2alpha inhibitor combination regimen.

Clinical Implications

The combination of pembrolizumab and belzutifan is a new adjuvant treatment option for patients with ccRCC at high risk of recurrence.

Conclusion

The approval of pembrolizumab and belzutifan marks a new development in the adjuvant treatment landscape for high-risk ccRCC patients.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
2. The ASCO Post, ASCO Post, 2026 -- Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence KEY POINTS
3. The ASCO Post — Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence KEY POINTS
4. The ASCO Post — Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence KEY POINTS
5. The ASCO Post — Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
6. FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma | FDA
7. Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). | Journal of Clinical Oncology